Biocept Inc (NASDAQ:BIOC)’s share price reached a new 52-week low during trading on Wednesday . The stock traded as low as $2.07 and last traded at $2.19, with a volume of 875 shares changing hands. The stock had previously closed at $2.25.

Several equities analysts have commented on the stock. Zacks Investment Research lowered shares of Biocept from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. ValuEngine downgraded shares of Biocept from a “buy” rating to a “hold” rating in a research note on Thursday, August 2nd. Finally, Dawson James restated a “buy” rating on shares of Biocept in a research note on Wednesday, October 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Biocept has an average rating of “Hold” and an average target price of $0.92.

The company has a current ratio of 1.20, a quick ratio of 1.08 and a debt-to-equity ratio of 0.42. The company has a market cap of $6.25 million, a price-to-earnings ratio of -0.09 and a beta of 1.64.

Biocept (NASDAQ:BIOC) last posted its quarterly earnings results on Tuesday, August 14th. The medical research company reported ($2.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.30) by $0.60. Biocept had a negative net margin of 642.49% and a negative return on equity of 587.80%. The company had revenue of $0.82 million for the quarter, compared to the consensus estimate of $1.09 million. On average, equities research analysts forecast that Biocept Inc will post -9.01 EPS for the current year.

A hedge fund recently raised its stake in Biocept stock. BlackRock Inc. grew its stake in Biocept Inc (NASDAQ:BIOC) by 1.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 794,302 shares of the medical research company’s stock after purchasing an additional 14,403 shares during the period. BlackRock Inc. owned about 34.99% of Biocept worth $159,000 as of its most recent filing with the Securities and Exchange Commission.

About Biocept (NASDAQ:BIOC)

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Featured Story: Diversification in Investing

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.